about
Racial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic reviewGenomics education for the public: perspectives of genomic researchers and ELSI advisorsRacial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing.Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.Mental health service use for adult patients with co-occurring depression and physical chronic health care needs, 2007-2010Patient-Centered Communication for Discussing Oncotype DX Testing.Oncology providers' perspectives on endocrine therapy prescribing and management.The effect of a celebrity health disclosure on demand for health care: trends in BRCA testing and subsequent health services use.Engagement with Genetic Information and Uptake of Genetic Testing: the Role of Trust and Personal Cancer History.The current state of implementation science in genomic medicine: opportunities for improvement.ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.Use and Costs for Tumor Gene Expression Profiling Panels in the Management of Breast Cancer From 2006 to 2012: Implications for Genomic Test Adoption Among Private Payers.Informed Consent and Decision Making Among Participants in Novel-Design Phase I Oncology Trials.Influence of provider factors and race on uptake of breast cancer gene expression profiling.The current state of funded NIH grants in implementation science in genomic medicine: a portfolio analysis.Twitter use at the 2016 Conference on the Science of Dissemination and Implementation in Health: analyzing #DIScience16.Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.Intentions to share exome sequencing results with family members: exploring spousal beliefs and attitudes.Delivery Of Cascade Screening For Hereditary Conditions: A Scoping Review Of The LiteratureA Qualitative Comparative Analysis of Combined State Health Policies Related to Human Papillomavirus Vaccine Uptake in the United StatesPossible barriers for genetic counselors returning actionable genetic research results across state linesLay Beliefs About the Accuracy and Value of Cancer ScreeningImplementation Challenges for Risk-Stratified Screening in the Era of Precision MedicineThe FDA authorization of direct-to-consumer genetic testing for three BRCA1/2 pathogenic variants: a twitter analysis of the public's response
P50
Q28082674-60585060-B94E-4D60-B550-0A9BBB8B7F64Q30573833-90248D3F-2089-406D-861A-7494642CF315Q36036034-7211C1E9-DB46-4BDD-A255-4EAC1655B7D4Q36914381-9404FCE2-78A2-4BA1-846B-1835B60973D7Q37064938-3C95E26F-5DBE-428B-95E0-7F1EE75B9F82Q37174496-D221504C-4E77-4C7D-BDB7-D8D04B912673Q37316792-546E1140-C034-4283-BC5B-62ABF961C1CBQ37746657-08C904C4-ADEB-4A19-A7D1-FB20027EB328Q39010918-36887134-28BE-4BCF-BB0E-39DB18E3FF11Q39024805-8E69A2C2-0C15-4B0C-8EC0-F7A21B6FD07AQ39106167-766349B2-CF78-4344-81F9-68ED04010EFAQ40804666-61641DEB-BD4B-4D92-8951-BD6A7FEC77C6Q47325013-C17F01DC-D7CE-4F9C-B842-F7CE699B952FQ48234815-5A9CCD65-9CBF-4EA1-84A5-1696569BEDF6Q48588147-2067ADAD-B8F7-45DB-BC86-F8C0599C64ECQ49843352-6FA5557B-1ED8-4E26-978D-4D760B0B0E14Q50869231-32337D66-944B-452F-A9A4-DDBE7247DA10Q53448365-E7A280F7-7FA6-44A4-AC1A-5D7E5AB0DEC8Q56969670-5874A789-19AA-4B4E-8A1A-885F544573F8Q87848667-EFF4199C-FCA4-4F21-A44A-80F44204C2A7Q87872779-1EB810C2-7833-4F71-8996-4D061D284030Q88090624-8EA52D54-6BC3-469E-949C-9A3585D0017BQ89440405-566B3847-5B85-4CAD-A0A2-7F7E720B3AB0Q89561133-4A141733-BDF6-4931-A3E7-6AE3226C5306
P50
description
researcher ORCID ID = 0000-0003-3434-2773
@en
name
Megan C Roberts
@ast
Megan C Roberts
@en
Megan C Roberts
@nl
type
label
Megan C Roberts
@ast
Megan C Roberts
@en
Megan C Roberts
@nl
prefLabel
Megan C Roberts
@ast
Megan C Roberts
@en
Megan C Roberts
@nl
P31
P496
0000-0003-3434-2773